Filter Results
:
(658)
Show Results For
-
All HBS Web
(4,324)
- Faculty Publications (658)
Show Results For
-
All HBS Web
(4,324)
- Faculty Publications (658)
Page 1 of
658
Results
→
- September 2024
- Case
Copenhagen Infrastructure Partners: Leading the Energy Transition
By: John Macomber and Maxwell Nii Laryea
A leading global infrastructure fund debates whether and when to become engaged in the electrolysis and distribution of hydrogen, as part of the hydrogen economy and the global transtion to a net zero energy world. The proposed billion dollar project consists of ...
View Details
Keywords:
Energy;
Infrastructure;
Energy Generation;
Renewable Energy;
Project Finance;
Energy Industry;
Spain
- 2024
- Working Paper
The Narrative AI Advantage? A Field Experiment on Generative AI-Augmented Evaluations of Early-Stage Innovations
By: Jacqueline N. Lane, Léonard Boussioux, Charles Ayoubi, Ying Hao Chen, Camila Lin, Rebecca Spens, Pooja Wagh and Pei-Hsin Wang
The rise of generative artificial intelligence (AI) is transforming creative problem-solving, necessitating new approaches for evaluating innovative solutions. This study explores how human-AI collaboration can enhance early-stage evaluations, focusing on the interplay...
View Details
Lane, Jacqueline N., Léonard Boussioux, Charles Ayoubi, Ying Hao Chen, Camila Lin, Rebecca Spens, Pooja Wagh, and Pei-Hsin Wang. "The Narrative AI Advantage? A Field Experiment on Generative AI-Augmented Evaluations of Early-Stage Innovations." Harvard Business School Working Paper, No. 25-001, August 2024. (Revised August 2024.)
- August 2024
- Case
Keurig: A Return to Growth
By: David Fubini and Patrick Sanguineti
By the early 2010s, Keurig Green Mountain (KGM) had lost the momentum that had made it the name in at-home coffee brewing in North America. Following a series of product missteps, negative media scrutiny, and ongoing challenges to its partner relationships, in late...
View Details
Fubini, David, and Patrick Sanguineti. "Keurig: A Return to Growth." Harvard Business School Case 425-009, August 2024.
- June 2024
- Case
SnapTravel: Betting on 'Super.com'
By: Reza Satchu and Tom Quinn
This case explores SnapTravel, a travel startup offering discounted hotel rooms, and its founders’ desire to pivot to a “super app” that saved customers money across many different purchase types. During the COVID-19 pandemic, Hussein Fazal and Henry Shi saw SnapTravel...
View Details
Keywords:
Business Growth and Maturation;
Business Plan;
Business Startups;
Change Management;
Disruption;
Transformation;
Volatility;
Customer Focus and Relationships;
Customer Value and Value Chain;
Decisions;
Income;
Entrepreneurship;
Geographic Scope;
Cross-Cultural and Cross-Border Issues;
Health Pandemics;
Surveys;
Knowledge Acquisition;
Knowledge Use and Leverage;
Leading Change;
Crisis Management;
Goals and Objectives;
Risk Management;
Consumer Behavior;
Game Theory;
Risk and Uncertainty;
Adaptation;
Diversification;
Expansion;
System Shocks;
Accommodations Industry;
Technology Industry;
Canada;
United States;
Las Vegas
- June 2024 (Revised August 2024)
- Case
Hospital for Special Surgery: Returning to a New Normal? (A)
By: Robert S. Huckman, Michael Lingzhi Li and Camille Gregory
Early on the morning of April 27, 2020, Justin Oppenheimer stood outside the entrance to the lobby of the Hospital for Special Surgery (HSS) Pavilion Building with mixed emotions. On one hand, Oppenheimer, HSS’ Enterprise Chief Operating Officer and Chief Strategy...
View Details
Keywords:
Operations Management;
Scheduling;
Optimization;
COVID-19;
Health Care and Treatment;
Operations;
Customer Focus and Relationships;
Disruption;
Health Industry;
United States
Huckman, Robert S., Michael Lingzhi Li, and Camille Gregory. "Hospital for Special Surgery: Returning to a New Normal? (A)." Harvard Business School Case 624-092, June 2024. (Revised August 2024.)
- April 2024 (Revised May 2024)
- Case
Anthropic: Building Safe AI
By: Shikhar Ghosh and Shweta Bagai
In March 2024, Anthropic, a leading AI safety and research company, made headlines with the launch of Claude 3, its most advanced AI model. This marked Anthropic’s bold entry into the multimodal GenAI domain, showcasing capabilities extending to both image and text...
View Details
Keywords:
AI and Machine Learning;
Corporate Accountability;
Corporate Social Responsibility and Impact;
Business Growth and Maturation;
Corporate Strategy;
Technology Industry;
United States
Ghosh, Shikhar, and Shweta Bagai. "Anthropic: Building Safe AI." Harvard Business School Case 824-129, April 2024. (Revised May 2024.)
- 18 Apr 2024
- Lecture
Innovation Opportunities Created by COVID-19 Can Help: And How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by...
View Details
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of...
View Details
Keywords:
Cost vs Benefits;
Decisions;
Judgments;
Values and Beliefs;
Global Strategy;
Health Care and Treatment;
Patents;
Growth and Development Strategy;
Growth Management;
Product Positioning;
Supply and Industry;
Supply Chain;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Philanthropy and Charitable Giving;
Opportunities;
Social Issues;
Equality and Inequality;
Health Industry;
Health Industry;
Denmark;
United States;
Europe;
China;
India;
Middle East;
North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- March 2024
- Case
Nomad: A License to Bank
By: Paul A. Gompers and Pedro Levindo
In late 2023, Lucas Vargas, CEO and co-founder of Nomad, a fintech that offered financial services in the United States for Brazilian residents, had to decide what to do to ensure the company’s continued expansion. Nomad launched its first product, a U.S. digital bank...
View Details
Keywords:
Mergers and Acquisitions;
Business Startups;
Customer Satisfaction;
Decision Making;
Entrepreneurship;
Banks and Banking;
Initial Public Offering;
Global Strategy;
Growth and Development Strategy;
Brands and Branding;
Marketing Strategy;
Product Launch;
Organizational Culture;
Going Public;
Ownership Stake;
Innovation and Invention;
Strategic Planning;
Business and Government Relations;
Business and Stakeholder Relations;
Risk and Uncertainty;
Business Strategy;
Competitive Advantage;
Corporate Strategy;
Diversification;
Expansion;
Vertical Integration;
Leadership;
Law;
Banking Industry;
Technology Industry;
Service Industry;
Brazil;
United States;
North America;
Latin America
- March–April 2024
- Article
How Companies Should Weigh in on a Controversy: A Better Approach to Stakeholder Management
By: David M. Bersoff, Sandra J. Sucher and Peter Tufano
Executives need guidance about managing their organizations’ engagement with societal issues—including hot-button topics such as gender, climate, and racial discrimination. Success in this realm does not mean avoiding public controversy or achieving unanimous support...
View Details
Keywords:
Values and Beliefs;
Social Issues;
Business and Stakeholder Relations;
Judgments;
Management Practices and Processes
Bersoff, David M., Sandra J. Sucher, and Peter Tufano. "How Companies Should Weigh in on a Controversy: A Better Approach to Stakeholder Management." Harvard Business Review 102, no. 2 (March–April 2024): 108–119.
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that...
View Details
Keywords:
Policy;
Government Legislation;
Health Care and Treatment;
Negotiation;
Price;
Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- January 2024
- Case
Frank Cornelissen: The Great Sulfite Debate (A)
By: Tiona Zuzul and Susan Pinckney
In 2018, artisanal Italian vineyard Frank Cornelissen was one of the world’s leading natural wine vineyards. Its founder, Frank Cornelissen, faced weather related conditions that forced him to have to decide between staying true to the tenets of the natural wine...
View Details
Keywords:
Budgets and Budgeting;
Business Earnings;
Plant-Based Agribusiness;
Family Business;
For-Profit Firms;
Small Business;
Change Management;
Transition;
Communication Strategy;
Cost vs Benefits;
Financial Management;
Financial Strategy;
Profit;
Revenue;
Spending;
Global Strategy;
Goods and Commodities;
Innovation Strategy;
Crisis Management;
Goals and Objectives;
Growth Management;
Success;
Strategic Planning;
Problems and Challenges;
Risk and Uncertainty;
Cognition and Thinking;
Reputation;
Adaptation;
Expansion;
Weather;
Mission and Purpose;
Values and Beliefs;
Food and Beverage Industry;
Agriculture and Agribusiness Industry;
Europe;
Italy
Zuzul, Tiona, and Susan Pinckney. "Frank Cornelissen: The Great Sulfite Debate (A)." Harvard Business School Case 724-391, January 2024.
- January 2024
- Teaching Note
Frank Cornelissen: The Great Sulfite Debate (A) & (B)
By: Tiona Zuzul
Teaching Note for HBS Case Nos. 724-391 and 724-398. In 2018, artisanal Italian vineyard Frank Cornelissen was one of the world’s leading natural wine vineyards. Its founder, Frank Cornelissen, faced weather related conditions that forced him to have to decide between...
View Details
Keywords:
Budgets and Budgeting;
Business Earnings;
Agribusiness;
Plant-Based Agribusiness;
Family Business;
For-Profit Firms;
Small Business;
Change Management;
Transition;
Communication Strategy;
Decision Making;
Cost vs Benefits;
Financial Management;
Financial Strategy;
Profit;
Revenue;
Spending;
Globalization;
Global Strategy;
Goods and Commodities;
Innovation Strategy;
Crisis Management;
Goals and Objectives;
Growth Management;
Success;
Strategic Planning;
Problems and Challenges;
Risk and Uncertainty;
Cognition and Thinking;
Reputation;
Strategy;
Adaptation;
Expansion;
Mission and Purpose;
Values and Beliefs;
Food and Beverage Industry;
Europe;
Italy
- January 2024
- Supplement
Frank Cornelissen: The Great Sulfite Debate (B)
By: Tiona Zuzul and Susan Pinckney
In 2018, artisanal Italian vineyard Frank Cornelissen was one of the world’s leading natural wine vineyards. Its founder, Frank Cornelissen, faced weather related conditions that forced him to have to decide between staying true to the tenets of the natural wine...
View Details
Keywords:
Budgets and Budgeting;
Business Earnings;
Plant-Based Agribusiness;
Business Startups;
Family Business;
For-Profit Firms;
Small Business;
Change Management;
Transition;
Communication;
Cost vs Benefits;
Decisions;
Entrepreneurship;
Environmental Sustainability;
Values and Beliefs;
Financial Management;
Financial Strategy;
Profit;
Revenue;
Spending;
Global Strategy;
Goods and Commodities;
Innovation Strategy;
Crisis Management;
Goals and Objectives;
Growth Management;
Success;
Strategic Planning;
Problems and Challenges;
Risk and Uncertainty;
Cognition and Thinking;
Reputation;
Adoption;
Expansion;
Weather;
Mission and Purpose;
Food and Beverage Industry;
Agriculture and Agribusiness Industry;
Europe;
Italy
Zuzul, Tiona, and Susan Pinckney. "Frank Cornelissen: The Great Sulfite Debate (B)." Harvard Business School Supplement 724-398, January 2024.
- January 2024 (Revised April 2024)
- Case
Target Malaria: Editing Mosquitoes through Gene Drives
By: Shikhar Ghosh and Shweta Bagai
Target Malaria, a non-profit research consortium, is exploring the application of CRISPR-Cas9 gene editing technology to combat malaria in Sub-Saharan Africa. Its approach uses gene drives, a revolutionary tool, to suppress the population of malaria-carrying...
View Details
Keywords:
Health Disorders;
Technological Innovation;
Nonprofit Organizations;
Business Strategy;
Genetics;
Ethics;
Governing Rules, Regulations, and Reforms;
United States;
United Kingdom;
Burkina Faso;
Africa
Ghosh, Shikhar, and Shweta Bagai. "Target Malaria: Editing Mosquitoes through Gene Drives." Harvard Business School Case 824-068, January 2024. (Revised April 2024.)
- January 2024 (Revised May 2024)
- Case
Generation Investment Management: Sustainable Investing in a Warming World
By: Vikram S. Gandhi, Michael Norris and David Allen
In September 2021, the sustainable investment firm Generation Investment Management (Generation) considered whether to add Schneider Electric to the focus list of companies in which it was prepared to invest. Dedicated to promoting a sustainable world through its...
View Details
Keywords:
Sustainable Investing;
Climate Change;
Environmental Sustainability;
Governance;
Private Equity;
Public Equity;
Financial Markets;
Investment Return;
Investment Activism;
Investment Funds;
Investment Portfolio;
Institutional Investing;
Corporate Social Responsibility and Impact;
Financial Services Industry;
United Kingdom;
England;
London
- 2024
- Working Paper
The Value of Open Source Software
By: Manuel Hoffmann, Frank Nagle and Yanuo Zhou
The value of a non-pecuniary (free) product is inherently difficult to assess. A pervasive
example is open source software (OSS), a global public good that plays a vital role in the economy
and is foundational for most technology we use today. However, it is...
View Details
Hoffmann, Manuel, Frank Nagle, and Yanuo Zhou. "The Value of Open Source Software." Harvard Business School Working Paper, No. 24-038, January 2024.
- January 2024
- Background Note
Evaluating Innovations in the Organization of Primary Care: What Type of Innovation Is It and How Well Does It Align with the Six Factors?
By: Regina E. Herzlinger and James Wallace
How can we evaluate if innovative health care ventures can do good—benefit society—and do well—become financially viable? This question is the topic of the first module in the Innovating in Health Care course book.
This note and "Health Stop (A): What Type... View Details
This note and "Health Stop (A): What Type... View Details
- January 2024
- Technical Note
The ICARUS Principles: What It Takes to Tackle the World
By: Debora L. Spar and Julia M. Comeau
Over the course of the 20th century, most of the world’s major multinational corporations framed their mission around Milton Friedman’s famous mantra: that the sole purpose of the firm is to maximize its shareholders’ profits. Recently, however, growing numbers of...
View Details
Keywords:
Purpose;
Mission;
Social Business;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Social Enterprise;
For-Profit Firms
Spar, Debora L., and Julia M. Comeau. "The ICARUS Principles: What It Takes to Tackle the World." Harvard Business School Technical Note 324-055, January 2024.
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.